Jiangsu Medomics Medical Technology Co., Ltd.,

美克医学

Home
Products
Products

Learn more 
Download
About
About

Jiangsu Medomics Medical Technology Co., Ltd., founded in October 2017, is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province.
Learn more 
- Company profile
- Honor and qualification
- Company profile
- Honor and qualification
Newsroom
Contact



Home
Products

 
Download
About

 
- Company profile
- Honor and qualification
Newsroom
Contact





Home
Products 
Infectious Disease STD Inflammation Dermatology Gastric Function
Download
About 
Company profile Honor and qualification
Newsroom
Contact

News Center

NEWS CENTER

Newsroom

Homepage

Newsroom

Company news

Medomics at Medica 2024

2024-11-25

MEDICA, the world’s leading trade fair for the medical industry, once again brought together top innovators, industry leaders, and professionals from across the globe. This prestigious event serves as a platform to showcase cutting-edge technologies, explore emerging trends, and foster meaningful collaborations in the healthcare sector. At this year’s MEDICA, our team proudly presented our latest in vitro diagnostic solutions, which garnered significant interest from visitors. Through engaging discussions and productive meetings, Medomics connected with industry partners, explored new opportunities, and strengthened our global network. Medomics extend our heartfelt thanks to everyone who visited our booth and made this event a memorable success. Stay tuned for more updates as we continue to innovate and shape the future of diagnostics!

Medic East Africa 2024

2024-09-16

Medomics recently participated in Medic East Africa 2024

Medomics at Medlab 2024

2024-02-23

Medlab Middles East 2024 reaffirmed its status as a crucial event for the medical laboratory sector.

Development of a cost-effective rapid detection of carbapenem-resistance Gram-negative bacteria laboratory workflow

2024-02-07

Spread of Carbapenemase-producing Enterobacterales (CPE) has become a major global public health threat and clinical concerns worldwide.

Medomics at Medica 2023

2023-11-24

As an important market for Medomics Medical in Europe, we have participated in the MEDICA exhibition for three years.

Overview of Sickle Cells Diseases and Introduction of a Cost-Effective Rapid Diagnostics Test

2023-11-08

Sickle cell disease (SCD), a group of related ß-hemoglobinopathies, is characterized by the predominance of sickle hemoglobin within patients’ red blood cells.

Medomics at EADV 2023

2023-10-20

Medomics at Medlab Asia 2023

2023-08-30

MEDLAB Asia was hold in Impact Exhibition & Convention Center Bangkok on 16 to 18 August 2023 showing the companies news of Thailand and internationals related to sectors Laboratories, Medicine.

Diagnostic value of dual-fluorescence staining in bacterial vaginosis

2023-08-03

Dual-fluorescence staining for the detection of bacterial diseases of the vagina exhibited acceptable consistency with Gram staining and performed well with respect to dyeing time, stability, and the interpretation of results. We argue that this method should be used in outpatient services.

Medomics at AACC 2023

2023-08-03

Medomics brought our respiratory rapid test, Gynecology rapid test, Antimicrobial resistance rapid test and Autostainer Machine to the world audience, and attracted countless scholars and customers.

Medomics in The 28th Chinese Medical Association National Academy of Dermatological Diseases Conference

2023-07-26

The 28th Chinese Medical Association National Academy of Dermatological Diseases Conference was held in China, Shenyang on July 13th-16th, 2023.

It's CRE，It's CRO，It is CPE

2023-05-10

Antimicrobial resistance (AMR) poses a serious global threat of growing concern to human, animal, and environment health. This is due to the emergence, spread, and persistence of multidrug-resistant (MDR) bacteria or “superbugs.”

Medomics has launched Candida albicans/ Trichomonas vaginalis/ Gardnerella vaginalis antigen Combo Test Kit (LFIA)

2023-03-27

Reproductive tract infection is an important part of systemic infection and has become a major public health problem in the world. Recent studies have shown that reproductive tract infection is closely related to tumor occurrence, infertility, ectopic pregnancy, premature rupture of membranes and premature delivery and so on. Almost all reproductive tract infections are accompanied by changes of genital tract microenvironment. There are several common pathogens which are easy to cause gynecologic diseases in women: 1)Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defenses. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. 2)Trichomonas vaginalis is a motile organism with a size comparable to a white blood cell. It has at least 4 flagella that provide undulating motility. The organism resides in the lumen of the urogenital tract. The organism releases cytotoxic proteins that destroy the epithelial lining. During an infection, the vaginal pH usually increases. 3)Gardnerella vaginalis is an anaerobic bacterium that resides in the normal vaginal flora. Normally, vaginal flora is predominated by the lactobacilli species, but when organisms such as gardnerella begin to overgrow and become the dominant species, this leads to bacterial vaginosis (BV). Bacterial vaginosis is characterized by the presence of clue cells, which are epithelial cells of the cervix that are covered with rod-shaped bacteria. According to statistics, 11% of women have BV detected during physical examination, and 36% - 60% among vaginitis patients in gynecological clinics. To meet the needs of market, Jiangsu Medomics Medical Technology Co., Ltd. has released a new product named Candida albicans/Trichomonas vaginalis/Gardnerella vaginalis antigen Combo Test Kit (LFIA). The test kit uses a double antibody sandwich method to detect Candida albicans, Trichomonas vaginalis, and Gardnerella vaginalis by latex microsphere immunochromatography, and is suitable for women with clinical symptoms of gynecological inflammation or suspected gynecological inflammation. The products have following advantages: On-site screening & quick results in 15 mins Low professional and training requirement Unaffected by medication Obtain pathogen antigen with high specificity Please CONTACT us if you are interested. We will be ready to provide you with the best possible service.

Medomics at Medlab 2023

2023-02-03

Medomics has released KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit

2022-11-18

KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit

Medomics at MEDICA 2022

2022-08-10

Medomics will attend Düsseldorf International Medical Fair in Germany in Nov. 14th - 17th, 2022. MEDICA is the leading international trade fair for medical sector. It is a very attractive event: more than 5100 exhibitors from 66 nations.

Medomics Medical contributes to global epidemic prevention and control, and has been approved two more certifications

2022-07-19

On June 28, 2022, Medomics Medical successfully obtained the TGA SARS-CoV-2 Antigen Test Kit (LFIA) Product Self-Test Certificate. This is the third certificate that Medomics Medical has obtained for this rapid test combo products in the Australian market after the professional version and the saliva oral self-test version.

Medomics Medical has awarded the EU CE certificate of the SARS-CoV-2 and Influenza A/B Antigen Combo rapid Test Kit (LFIA)

2022-07-19

On May 24th, Medomics Medical independently developed SARS-CoV-2 &Influenza A/B Antigen Combo Rapid Test Kit(LFIA) that can be used for this self test rapid combo has obtained the CE self-test certificate issued by PCBC (1434), which means that Medomics Medical's triple inspection and self-test products have fully complied with the IVDD directive and the latest EU MDCG2021-21 Regulatory requirements, it can be sold in the EU and countries that recognize the EU CE self-test certificate. Medomics is the third IVD company to obtain the CE certificate of triple inspection and self-test, and the first company in the world to pass the audit and certification of this self test rapid combo inspection and self-test certificate by the well-known announcement agency UL.

Nearly 10 million test kits were released quickly, Medomics Medical helped Hong Kong to fight the epidemic

2022-03-17

A few days ago, the novel coronavirus in Hong Kong has touched people's hearts. In order to support Hong Kong's fight against the epidemic, nearly 10 million SARS-CoV-2 Test Kits from Jiangsu Medomics Medical Company, an enterprise in the Biomedical Valley Park of Jiangbei New Area, have been released quickly to help Hong Kong compatriots overcome the difficulties. In the Past few days, there are many large wooden boxes and heavy transport vehicles written "fight epidemic with one heart, cheer for Hong Kong" "rush to help Hong Kong",beside the open space and roads of Zhongdan Park. These wooden boxes and vehicles are loaded and transported with SARS-CoV-2 Test Kits ordered by the Hong Kong Special Administrative Region Government from Medomics Medical Company. In order to produce and raise the batch of anti-epidemic materials urgently needed in Hong Kong as soon as possible, all employees of Medomics Medical company worked overtime and 24-hour shifts for more than a week before, and finally delivered nearly 10 million SARS-CoV-2 Test Kits. Under the supervision of Nanjing Customs, Medomics Medical Company relies on the rapid inspection channel system for novel coronavirus test kits for Hong Kong which established by the Jiangsu Pilot Free Trade Zone (Nanjing Area) Biomedical Centralized Inspection Platform, and divides the kits into 13 batches. Under the protection of same-day declaration, same-day inspection, and same-day release, it will be shipped to Hong Kong at the fastest speed to solve local urgent needs. It is understood that this batch of SARS-CoV-2 Test Kits supported by Medomics Medical company has obtained the EU CE certificate, the German BfArM authorization, the Australian TGA certification, the French whitelist certification and many other authorized certifications from many countries and regions with a good reputation and evaluation. In addition to Hong Kong, the sales scope of SARS-CoV-2 Test Kits developed by Medomics Medical company has covered more than 60 countries and regions around the world. Join hands to fight against the epidemic and overcome the difficulties together. Enterprises in the park, including Medomics Medical company, are leading the charge in epidemic prevention and control, developing and producing test kits, shouldering the heavy responsibility of antigen detection, and building an epidemic defense line with scientific research strength.

Medomics Medical SARS-CoV-2 Antigen Self-Testing Kit has obtained the EU CE certificate!

2021-11-12

Medomics Medical SARS-CoV-2 Antigen Test Kit has participated in the QCMD EQA Pilot Study initiated by Randox Laboratory in UK with HIGHLY SATISFACTORY result!

2021-11-05

Focusing on global epidemic prevention and control, Medomics Antigen Test Products Completed India Registration

2021-06-17

Opening a new mode of agency -- the exchange meeting between GCHW and Jiangsu Medomics project was successfully held

2020-11-06

Golden autumn in October, laurel fragrance, October 31, under the beautiful Qinhuai River, under the antique Dinghuai Gate, the annual meeting of Obstetrics and Gynecology of Jiangsu Medical Association, the exchange meeting of the new project of Gynecological Reagents by Guokong Wende & Jiangsu Medomics Convened.

[Reproduced] Dropping blood can detect the COVID-19! Zhong Nanshan's team successfully developed a 15-minute result test kit.

2020-03-11

Nandu report :Recently, Zhong Nanshan's team successfully developed a technology which was tested by dripping, 15 minutes to issue results and IgM-IgG combined antibodies test kit for COVID-19. This kit can not only be used as a supplementary test for patients with negative viral nucleic acid tests to improve the clinical diagnosis rate ,but also as a means of rapid screening, indicating that a more convenient screening method will be come out soon !





Industry trends

2024

11-25

Medomics at Medica 2024

2024

09-16

Medic East Africa 2024

Medomics recently participated in Medic East Africa 2024

2024

02-23

Medomics at Medlab 2024

Medlab Middles East 2024 reaffirmed its status as a crucial event for the medical laboratory sector.

2024

02-07

Development of a cost-effective rapid detection of carbapenem-resistance Gram-negative bacteria laboratory workflow

Spread of Carbapenemase-producing Enterobacterales (CPE) has become a major global public health threat and clinical concerns worldwide.

2023

11-24

Medomics at Medica 2023

As an important market for Medomics Medical in Europe, we have participated in the MEDICA exhibition for three years.

2023

11-08

Overview of Sickle Cells Diseases and Introduction of a Cost-Effective Rapid Diagnostics Test

Sickle cell disease (SCD), a group of related ß-hemoglobinopathies, is characterized by the predominance of sickle hemoglobin within patients’ red blood cells.

Email Us overseas@medomics-dx.com
Call Us +86-025-58601060
COVID-19 Solution
Top

FOLLOW MEDOMICS

Product Center

Honor and qualification

Phone： (+86) 025 - 58601060

E-mail: overseas@medomics-dx.com
Address：3 / F, Building D, Phase II, Zhongdan Ecological Life Science Industrial Park, 3-1 Xinjinhu Road, Jiangbei New District, Nanjing

Email Us
COVID-19 Solution
Call Us (+86) 025 - 58601060
top

苏ICP备18065762号

Jiangsu Medomics Medical Technology Co,Ltd Powered By www.300.cn

Products  

About  

Products

 

About

 